By
Kyle Brasseur2023-12-18T20:48:00
A long-running initiative by the Department of Justice (DOJ) and Federal Trade Commission (FTC) to modernize their joint merger guidelines reached its conclusion Monday.
The agencies issued their 2023 Merger Guidelines, following a nearly two-year process of public feedback, workshops, and review. The finalized guidelines replace previous guidance published separately on vertical mergers and horizontal mergers in 2020 and 2010, respectively.
“The 2023 Merger Guidelines reflect the new realities of how firms do business in the modern economy and ensure fidelity to statutory text and precedent,” said FTC Chair Lina Khan in a joint press release.
2024-09-09T18:28:00Z By Aaron Nicodemus
A privately held family company and its CEO, who announced a $10 billion bid to buy U.S. Steel without having the cash on hand, will pay $600,000 in penalties to the Securities and Exchange Commission for making materially false statements.
2024-08-07T17:42:00Z By Adrianne Appel
A hospitality company agreed to pay $3.5 million and appoint an anti-trust compliance officer to settle allegations by the Department of Justice that it engaged in illegal pre-merger activity.
2023-10-27T16:25:00Z By Kyle Brasseur
It’s no secret the U.S. healthcare competition system has significant flaws. Where the debate exists is in determining the source of the issues and how to fix them, according to Deputy Assistant Attorney General Andrew Forman of the Department of Justice’s Antitrust Division.
2025-12-10T15:30:00Z By Neil Hodge
For the past decade, Europe has led in creating strong but flexible rules for data use and safe AI development. The EU’s new plans to simplify key data privacy and AI governance measures have received a mixed response.
2025-12-05T19:25:00Z By Oscar Gonzalez
The U.S. Securities and Exchange Commission’s (SEC) Division of Examinations released its 2026 examination priorities, which give companies a roadmap of areas of heightened risk and regulatory focus for next year.
2025-12-04T22:15:00Z By Ruth Prickett
Regulation is a matter of life and death in the pharmaceutical industry. Rules to combat practices that can kill have been in force for decades, but tech developments are rapidly creating new risks and focusing lawmakers’ attention on areas where some compliance teams may lack experience.
Site powered by Webvision Cloud